MedTrace Logo

The Effect of Perthes' Disease on Hip Cartilage

NCT00958464 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-10-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether Perthes' disease has caused detectable hip cartilage damage in young people who have reached the healed stage of the disease.

Conditions

  • Perthes' Disease

Interventions

PROCEDURE

MRI

MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Kishore Mulpuri, Dr. · University of British Columbia

  • David Wilson, Dr. · University of British Columbia

Eligibility

Min Age
17 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00958464 on ClinicalTrials.gov